330793-99-2Relevant academic research and scientific papers
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
Wang, Aoli,Li, Xixiang,Chen, Cheng,Wu, Hong,Qi, Ziping,Hu, Chen,Yu, Kailin,Wu, Jiaxin,Liu, Juan,Liu, Xiaochuan,Hu, Zhenquan,Wang, Wei,Wang, Wenliang,Wang, Wenchao,Wang, Li,Wang, Beilei,Liu, Qingwang,Li, Lili,Ge, Jian,Ren, Tao,Zhang, Shanchun,Xia, Ruixiang,Liu, Jing,Liu, Qingsong
, p. 8407 - 8424 (2017)
FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of our previous study that ibrutinib (9) exhibited selective and moderate inhibitory activity against FLT3-ITD positive AML cel
FLT3 kinase novel inhibitors and use thereof (by machine translation)
-
Paragraph 0153; 0158; 0159, (2018/01/05)
The present invention provides FLT3 kinase novel inhibitors, of formula (I) compound or its pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite, or prodrug. The invention also provides formula (I) compound of the pharmaceutical comp
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
-
Page/Page column 118; 119; 120, (2013/03/26)
Disclosed herein are compounds of Formula (II) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical c
Pyrazolopyrimidines as therapeutic agents
-
, (2008/06/13)
The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
Pyrazolopyrimidines as therapeutic agents
-
, (2008/06/13)
The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.
